Oncolytic virus encoding decorin and the CD40 ligand boosts T-cell response and achieves a durable antitumor response during breast cancer treatment. [PDF]
Ning Y +8 more
europepmc +1 more source
Bridging mechanism and clinic: unlocking the full potential of oncolytic virus-based immunotherapy. [PDF]
Hua X +6 more
europepmc +1 more source
Enhancing the therapeutic potential of oncolytic virotherapy for melanoma treatment
reservedMelanoma remains a globally relevant malignancy. Although various treatments have been developed over time, few are effective against rarer mutations.
PAROLIN, BEATRICE
core
Oncolytic virus OHSV2 induces pyroptosis in bladder cancer cells via the TLR4/NLRP3/Caspase-1/GSDMD pathway. [PDF]
Xu J +9 more
europepmc +1 more source
Stimulate-and-retain hydrogel strategy integrating oncolytic virus and oxaliplatin for dual ICD-inducing antitumor immunity. [PDF]
Zhang D +9 more
europepmc +1 more source
Clinical dose of enoxaparin enhances oncolytic virus M1 infection and antitumor efficacy in human bladder cancer. [PDF]
Xiao X +14 more
europepmc +1 more source
Intraperitoneal delivery of the oncolytic virus CF17 improves tumor immunogenicity and survival in gastric cancer peritoneal metastasis. [PDF]
Zhang Z +11 more
europepmc +1 more source
Development and Validation of a Rapid Titer Assay for the Oncolytic Virus oHSV2 Expressing a PD-L1/CD3 Bispecific Antibody. [PDF]
Zhang S +6 more
europepmc +1 more source
Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors. [PDF]
Merchan JR +12 more
europepmc +1 more source

